论文部分内容阅读
用LSAB免疫组比法，对20例胃癌、22例异型增生、30例肠化生及13例正常组织进行了ras－p21和突变型p53蛋白表达的检测．结果发现在ras－p21和突变型p53均阳性的胃癌组织分别为13例（65.0％）和12例（60．0％）；异型增生为12例（54．5％）和10例（45．4％）；肠化生11例（36．6％）和4例（13．3％），正常组织全部阴性。卡方检验结果，p值均小于0.05。胃癌、异型增生和肠化生三种组织中p21和p53联合表达分别为8例（40．0％）、7例（31．8％）和2例（6．7％）。提示ras原癌基因和p53抑癌基因突变是胃癌的早期事件，p21和p53可作为胃癌临床细胞学诊断的新指标。
Using LSAB immunohistochemistry method, ras-p21 and mutant p53 protein expression were detected in 20 cases of gastric cancer, 22 cases of dysplasia, 30 cases of metaplasia and 13 cases of normal tissues. The results showed that ras-p21 and mutant p53 were positive in 13 cases (65.0%) and 12 cases (60.0%), respectively; dysplasia in 12 cases (54.5%) and 10 cases (45. 4%); Intestinal metaplasia in 11 cases (36.6%) and 4 cases (13.3%), all normal tissues were negative. Chi square test results, p values were less than 0.05. The combined expressions of p21 and p53 in gastric cancer, dysplasia and intestinal metaplasia were 8 cases (40.0%), 7 cases (31.8%) and 2 cases (6.7%). It is suggested that ras proto-oncogenes and p53 tumor suppressor gene mutations are early events of gastric cancer, and p21 and p53 may serve as new indicators for the clinical cytology diagnosis of gastric cancer.